STARPHARMA LODGES APPLICATION TO FDA FOR CLINICAL TRIALS

Melbourne (Australia), 30 June 2003: Starpharma Pooled Development Limited (ASX: SPL) today announced the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for permission to commence Phase I human clinical trials on the vaginal microbicide drug product SPL7013 gel (VivaGel™).

This first application for regulatory approval is for an HIV preventative, but the compound also has activity against Chlamydia and Genital Herpes.

Dr John Raff, the CEO of Starpharma said: "This is the first time that a defined dendrimer-based nanostructure has been submitted to the US regulatory system for approval as a pharmaceutical drug, and is the result of a huge amount of research, development and analytical effort."

The application has been lodged by Starpharma Limited, a wholly owned subsidiary of Starpharma Pooled Development Limited.

Starpharma Limited, a wholly owned subsidiary of Starpharma Pooled Development Limited (SPL), is a biopharmaceutical company focused on the development and application of dendrimer nanotechnologies as drugs against major diseases. Starpharma Limited has an extensive intellectual property portfolio relating to dendrimer nanotechnology. SPL also has a 49.9% equity in a US based company – Dendritic Nanotechnologies Inc. (DNT) – established with the US pioneer of dendrimer nanotechnology Dr Donald Tomalia.

CONTACTS:

Dr John Raff
Chief Executive Officer
+61 3 8532 2701
www.starpharma.com

Mr Ben Rogers
Company Secretary
+61 3 8532 2702